0001104659-24-006396.txt : 20240125
0001104659-24-006396.hdr.sgml : 20240125
20240125060210
ACCESSION NUMBER: 0001104659-24-006396
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Francomano Robert
CENTRAL INDEX KEY: 0001797467
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33958
FILM NUMBER: 24558456
MAIL ADDRESS:
STREET 1: C/O STEMLINE THERAPEUTICS, INC.
STREET 2: 750 LEXINGTON AVENUE, 11TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc.
CENTRAL INDEX KEY: 0001390478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 6462005278
MAIL ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Galena Biopharma, Inc.
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: GALENA BIOPHARMA, INC.
DATE OF NAME CHANGE: 20110922
4
1
tm243935-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-22
0
0001390478
SELLAS Life Sciences Group, Inc.
SLS
0001797467
Francomano Robert
C/O SELLAS LIFE SCIENCES GROUP, INC.,
7 TIMES SQUARE, SUITE 2503
NEW YORK
NY
10036
0
1
0
0
Chief Commercial Officer
0
Common Stock
2024-01-22
4
A
0
20000
0.00
A
40918
D
Stock Option (Right to Buy)
0.5195
2024-01-22
4
A
0
30000
0
A
2034-01-22
Common Stock
30000
30000
D
The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Robert Francomano
2024-01-24